

DEC 14 2006

PTO/SB/21 (08-04)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/543,117	
	Filing Date	07/22/2005	
	First Named Inventor	Jung, Man-Kil	
	Art Unit	1625	
	Examiner Name	Owens, Amella A.	
Total Number of Pages in This Submission	37	Attorney Docket Number	2017-05

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Certified Translation of Priority Document; and Translation Declaration
Remarks Current application status is 'Notice of Allowance not Mailed'. Certified copy of priority document in non-English version submitted at PCT International Stage. This submission is in response to the examiner's request.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	IPLA P.A.		
Signature	/James E. Bame/		
Printed name	James E. Bame		
Date	12/14/2006	Reg. No.	44521

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature	/Yvette Park/		
Typed or printed name	Yvette Park	Date	12/14/2006


This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Translator Declaration

I am Yeosook Ko residing at 977-15, #301 Mirim Courtvill, Seijung 4 Dong, Yangcheon Gu, Seoul, Republic of Korea and declare that I am an experienced Korean-to-English translator and performed a direct translation of the Korean Priority Document No. 10-2003-00045111 into English language to a full extent of my knowledge and experience. The English translation copy is attached hereto.

(signature)
full name

Yeosook Ko


Date: December 9, 2006

PCT/KR 2004/000086
RO/KR 19.01.2004

REC'D 10 FEB 2004

WIPO

PCT



별첨 사본은 아래 출원의 원본과 동일함을 증명함.


This is to certify that the following application annexed hereto
is a true copy from the records of the Korean Intellectual
Property Office.

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

출원번호 : 10-2003-0004511
Application Number

출원년월일 : 2003년 01월 23일
Date of Application JAN 23, 2003

출원인 : 정만길
Applicant(s) JUNG MAN GIL



2004 년 01 월 19 일

특 허 청
COMMISSIONER



Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/548,117

[Bibliographic Data]

[Document]	Patent Application
[Right]	Patent
[Recipient]	KIPO Commissioner
[Reference Number]	0001
[Filing Date]	Jan 23, 2003
[Int. Class]	A61F
[Title in Korean]	디옥소아테미시닌 유사체, 그의 제조방법 및 그
를 포함하는 항암제	
[Title in English]	DEOXOARTEMISININ ANALOGS, PROCESS
FOR THEIR PREPARATION, AND ANTICANCER AGENT COMPRISING	
THEM	
[Applicant]	
[Name]	JUNG, MAN KIL
[Code]	4-2003-002394-1
[Agent]	
[Name]	PARK, SANG KI
[Code]	2003-003997-3
[Inventor]	
[Name]	JUNG, MAN KIL
[Code]	4-2003-002394-1
[Substantive Examination]	APPROVAL
[Purpose]	Apply like above according to Patent Law Article
42, Agent. PARK, SANG KI	
[Fee]	
[Basic filing fee]	20 pages KRW 29,000
[Additional filing fee]	28 pages KRW 28,000
[Priority claiming fee]	0 KRW 0
[Requesting fee for substantial examination]	6 KRW 301,000
[Total]	KRW 358,000
[Discount]	Personal Inventor, 70% down
[Total]	KRW 107,400

Translation of Priority Document No. 10-2003-0004611 for U.S. Application No. 10/543,117

[Abstract]

The present invention relates to a new deoxoartemisinin dimer and trimer, which have excellent anticancer activity and lower toxicity and are stable to acids, to a new deoxoartemisinin monomer of intermediate thereof, to preparations thereof, and to anticancer agents comprising the deoxoartemisinin dimer or trimer.

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

[Specification]


DEOXOARTEMISININ ANALOGS, PROCESS FOR THEIR PREPARATION,
AND ANTICANCER AGENT COMPRISING THEM

[Technical Field]

The invention relates to deoxoartemisinin analogs, process for their preparation and anticancer agent comprising them. More particularly, the present invention relates to a new deoxoartemisinin dimer and trimer, which have excellent anticancer activity and lower toxicity and are acid stable, to a new deoxoartemisinin monomer of intermediate thereof, to preparations thereof, and to anticancer agents comprising the deoxoartemisinin dimer or trimer.

[Background Art]

Artemisinin (Qinghaosu) (I), a sesquiterpene lactone endoperoxide, is the first natural trioxane isolated from *Artemisia annua*, L.





I

The artemisinin is of special biological interest because of its outstanding antimalarial activity and outstanding activity against *pneumocystis carinii* and *toxoplasma gondii*.

The anti-human immunodeficiency virus (HIV) activity of artemisinin derivatives has been also reported. Artemisinin has been subjected to a number of reviews because of its novel structure and outstanding antimalarial activity. Most first generation C-12 acetal type derivatives are hydrolytically unstable. Also, most semi-syntheses have involved replacing the C-12 acetal functionality in ether derivatives by less hydrolytically prone functional groups. Recently, however, C-12 non-acetal-type deoxoartemisinin (III) prepared from either artemisinin of formula (I) or artemisinic acid of formula (II) has been reported to show more

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

antimalarial activity than that of artemisinin both *in vitro* and *in vivo* (see Jung, M.; Li, X.; Bustos, D. A.; ElSohly, H. N.; McChesney, J. D., A Short and Stereospecific Synthesis of (+)-Deoxyartemisinin and (-)-Deoxodesoxyartemisinin, *Tetrahedron Lett.*, **1989**,30, 5973-5976 and Jung, M.; Li, X.; Bustos, D. A.; ElSohly, H. N.; McChesney, J. D.; Milhous, W. K., Synthesis and Antimalarial Activity of (+)-Deoxyartemisinin, *J. Med. Chem.*, **1990**,33, 1516-1518).



Non-acetal-type analogs of deoxyartemisinin recently received attention owing to their better bioavailability, such as acid stability, than acetal-type analogs. Furthermore, evidence that analogs not possessing exo-oxygen at C-12 are less neurotoxic in animal studies than acetal type artemisinin is also emerging and may thus lead to the future abandonment of the currently clinically used acetal-type analogs (e. g. , arteether, artemether, artesunate and artelinic acid). After the preparation of 12-n-butyldeoxyartemisinin as the first hydrolytically stable non-acetal type analog containing a C-C bond at C-12 was reported, a series of non-acetal-type derivatives including a few of heteroaryl and unsaturated substituents a C-12 have been prepared (See Jung, M. ; Bustos, D. A.; ElSohly, H. N.; McChesney, J. D., A Concise and Stereoselective Synthesis of (+)-12-n-Butyldeoxyartemisinin, *Synlett*, **1990**,743-744 and Chorki, F. ; Crousse, B.; Bonnet-Delpon, D.; Begue, J. P.; Brigaud, T.; Portella, C., C-10 Fluorinated Derivatives of Dihydroartemisinin: Difluoromethylene Ketones, *Tetrahedron Lett.*, **2001**, 42, 1487-1489).

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

Although most studies have focused on antimalarial activities, a few research groups have recently reported on cancer cell toxicity of artemisinin and its related derivatives. (see Woerdenbag, H. J.; Moskal, T. A.; Pras, N.; Maringle, T. M.; El-Feraly, F. S.; Kampinga, H. H.; Konings, A. W. T., Cytotoxicity of Artemisinin-related Endoperoxides to Ehrlich ascites Tumor cells, *J Nat. Prod.*, **1993**, 56, 849 and Wu, J-M.; Shan F.; Wu, G-S.; Li, Y.; Ding, J.; Xiao, D.; Han, J-X.; Atassi, G.; Leonce, S.; Caignard, D-H.; Renard, P., Synthesis and Cytotoxicity of Artemisinin derivatives containing Cyanoarylmethyl group, *Eur. J. Med. Chem.*, **2001**, 36 (5), 469-479). Because of their higher rate of cell division, most cancer cells express a higher surface concentration of transferrin receptors than normal cells and have high rates of iron intake. A unique structure bearing endoperoxide could be a trigger for the generation of active oxygen radicals via hemolytic cleavage of the weak oxygen-peroxide bond accelerated by higher ferrous ion concentration of cancer cell, which may mediate for the selective and preferable damage to vital cellular structures of the relatively active cancer cells. Although some dimers of acetal type derivatives of artemisinin have been prepared and show anticancer activities, yields are low and most of them possess either aromatic linkers or still acetal types at the C-12 position, which are neurotoxic, acid unstable, and show low anticancer activities (see Galal, A. M.; Ahmad, M. S.; El-Feraly, F. S., Preparation and Characterization of a New Artemisinin-Derived Dimer, *J. Nat. Prod.*, **1996**, 59, 917-920; Posner, G. H.; Polypradith, P.; Parker, M. H.; O'Dowd, H.; Woo, S-H.; Northrop, J.; Krasavin, M.; Dolan, P.; Kensler, T. W.; Xie, S.; Shapiro, Antimalarial, Antiproliferative, and Antitumor Activities of Artemisinin-Derived, Chemically Robust, Trioxane Dimers., *J. Med. Chem.*, **1999**, 42, 4275-4280; and Ekthawatchai, S.; Kamchonwongpaisan, S.; Kongsaree, P.; Tamchompoo, B.; Thebtaranonth, Y.; Yuthavong, Y., C-16 Artemisinin Derivatives and Their Antimalarial and Cytotoxic Activities: Synthesis of Artemisinin Monomers, Dimers, Trimers, and Tetramers by Nucleophilic Additions to Artemisitene, *J. Med. Chem.*, **2001**, 44, 4688-4695).

[Disclosure of Invention]

Surprisingly, we found that deoxoartemisinin dimer and trimer had excellent anticancer activity, by preparing non-acetal-type deoxoartemisinin dimer and

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

trimer having no linker containing C-O bonds, aromatic or unsaturated groups at C-12 position and then testing the anticancer activity thereof.

Accordingly, it is an object of the present invention to provide a deoxoartemisinin dimer and trimer having excellent anticancer activity.


It is another object of the present invention to easily prepare the deoxoartemisinin dimer and trimer in high yield.

It is another object of the present invention to provide anticancer agents comprising the deoxoartemisinin dimer and trimer.



It is another object of the present invention to provide a deoxoartemisinin monomer of intermediate for preparing the deoxoartemisinin dimer and trimer in high yield.

It is another object of the present invention to easily prepare the deoxoartemisinin monomer in high yield.

Deoxoartemisinin dimer and trimer of the present invention have the following formula (IV):




In this formula ((IV), Y is -S-, -SO₂-





Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

or




The deoxyartemisinin dimer and trimer of the present invention are prepared from the deoxyartemisinin monomers of formula (V) and (VI), respectively, as shown in Schemes 1, 2 and 3 below.



The deoxyartemisinin dimer of the present invention having sulfide-or sulfonyl group-bearing linker is prepared by bis-nucleophilic coupling reaction of 12-bromoethyldeoxyartemisinin monomers (V), as shown in Scheme 1 below. Particularly, the deoxyartemisinin dimer (IVa₁) is prepared by reacting 1 mole of sodium sulfide with 2 moles of 12-bromoethyldeoxyartemisinin (V) and dimer (IVa₂) is prepared by oxidizing the dimer (IVa₁) with oxidizing agent such as meta-chloroperoxybenzoic acid (m-CPBA). In a similar fashion, the deoxyartemisinin dimer (IVb₁) is prepared by 1 mole of 1,3-propanedithiol with 2 moles of 12-bromoethyldeoxyartemisinin (V) and the dimer (IVb₂) is prepared by reacting the dimer (IVb₁) with an oxidizing agent such as m-CPBA.

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

[Scheme 1]




The deoxyartemisinin dimer of the present invention having amide groups-containing linker is prepared from 12-aminoethyldeoxyartemisinin (VI), as shown in Scheme 2 below.

Particularly, the deoxyartemisinin dimer (IVc) is prepared by coupling 12-aminoethyldeoxyartemisinin (VI) with 12-carboxylethyldeoxyartemisinin (VII) in the presence of a catalyst such as 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC)/10-hydroxybenzotriazole (HOBt).

On the other hand, the deoxyartemisinin dimer (IVd) is prepared by directly coupling 12-aminoethyldeoxyartemisinin (VI) with protected glutarate in the presence of a catalyst such as EDC/HOBt, removing the benzyl group of the ester, coupling the resultant product with 12-aminoethyldeoxyartemisinin (VI) in the presence of a catalyst such as EDC/HOBt and then deprotecting the t-BOC protected group of the amino group of the resultant product.

[Scheme 2]


Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117



The deoxoartemisinin trimer (IVe) of the present invention is prepared by coupling 12-carboxylethyldeoxoartemisinin (VII) with L-glutamic diethylester in the presence of a catalyst such as EDC/HOBt, hydrolyzing the two ester groups of the product from the previous step and then doubly coupling the product from the previous step with 2 moles of 12-aminoethyldeoxoartemisinin (VI) in the presence of a catalyst such as EDC/HOBt, as shown in Scheme 3 below.

[Scheme3]


Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117



The novel deoxoartemisinin monomers (V and VI), which are intermediates for preparing the deoxoartemisinin dimer and trimer of the present invention, are prepared from 12-vinyldihydroartemisinin alcohol (XIII), as shown in Scheme 4 below. A 12-vinyldihydroartemisinin alcohol (XIII) can be synthesized from artemisinic acid (II) by a known synthetic route (see Jung et al., *A Concise and Stereoselective Synthesis of (+)-12-n-Butyldeoxoartemisinin*, *Synlett*, 1990, 743-744). Since artemisinin is much more expensive than artemisinic acid and a direct introduction of a C-C bond at C-12 of artemisinin may cause a destruction of the biologically essential endoperoxide, the artemisinic acid is used. Particularly, 12-bromoethyldeoxoartemisinin (V) is prepared by direct hydroborative oxidizing a terminal olefin of 12-vinyldihydroartemisinin alcohol (XIII), brominating the resultant product with $\text{CBr}_4/\text{PPh}_3$, photooxygenative cyclizing the resultant product by a known procedure (see Jung, M et al., *supra*). On the other hand, 12-aminoethyldeoxoartemisinin (VI) is prepared by reacting 12-bromoethyldeoxoartemisinin (V) with sodium azide and then reducing the azide of the resultant product. In the preparation of 12-bromoethyldeoxoartemisinin (V) and 12-aminoethyldeoxoartemisinin (VI) according to the above-mentioned procedures, 12B-epimer is obtained exclusively.

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

[Schema 4]



The deoxoartemisinin dimer and trimer of the present invention is C-12 non-acetal-type and have no linker containing C-O bonds, aromatic or unsaturated groups at C-12 position, and thus is less neurotoxic, acid stable and have a higher anticancer activity. Therefore, the dimer and trimer of the present invention can be used as an effective anticancer agent for oral administration.

An anticancer agent containing the deoxoartemisinin dimer or trimer of the present invention as an effective constituent can be administered orally (e. g. , ingestion or inhalation) or parenterally (e. g. , Intravenous injection, subcutaneous injection, percutaneous absorption, etc.) and can be prepared in the various form of tablets, capsules, granules, fine subitiae, powders, sublingual tablets, suppositories, ointments, injections, emulsions, suspensions, drug-treated syrups, etc. , depending on its use. The above-mentioned various type of anticancer agents are prepared by a known technique using pharmaceutically acceptable conventional carrier such as excipient, binder, disintegrator, lubricant, antiseptic, antioxidant, isotonic agent, buffer, coating, sweetening, solubilizer, base, dispersion, stabilizer, colorant.

Translation of Priority Document No. 10-2008-0004611 for U.S. Application No. 10/543,117

In the preparation of the agent, the content of the compounds of the present invention depends on the type of agents, but preferably ranges from 0.01 to 100% by weight.

The dosage of the anticancer agent of the present invention will vary depending on a variety of factors, such as, the kind of mammalian including human to be treated, the severity of the disease and the physician's judgment. Typically, for oral administration, the anticancer agent of the present invention can be administered as an effective constituent in the amount of 0.01 to 50mg per kg body weight per day and, for parenteral administration, in the amount of 0.01 to 10mg per kg body weight per day.

The anticancer agent of the present invention can be administered at one time or at several times per day and its dosage can be varied depending on the severity of the disease and the physician's judgment.

The present invention is further described in the following examples. These examples illustrate the invention only and are not to be construed as limiting the scope of the present invention in any way.

[EXAMPLES]

Example 1: Synthesis of 12-(2'-bromoethyl) deoxoartemisinin (V)

(1) Synthesis of 12-(2'-hydroxyethyl) dihydroartemisinin alcohol (XIV).

12-vinyldihydroartemisinin alcohol (XIII) (568mg, 2.290mmol), prepared by a known procedure (see Jung et al., *A Concise and Stereoselective Synthesis of (+)-12-n-Butyldeoxoartemisinin*, *Synlett*, 1990,743-744), was slowly added to THF solution containing 0.5M of 9-borobicyclo [3.3.1] nonane (9BBN) (9.1mL, 4.58mmol) under nitrogen atmosphere and the resulting mixture was stirred at room temperature for 30 minutes. Then, to this solution was added 30%-H₂O₂/3N-NaOH (1/1, 2mL) and the resulting solution was stirred at room temperature for 1 hour. The reaction mixture was extracted with ether (40mL x 2) and washed with saturated NaHCO₃ (20mL) and brine (20mL x 2). The extract was dried over MgSO₄, concentrated in vacuo and purified by silica gel

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/549,117

column (hexane/ethyl acetate = 1/1 as eluent) to afford 12- (2'-hydroxyethyl) dihydroartemisinin alcohol (XIV) as a colorless oil (97% yield).

$^1\text{H-NMR}$ (CDCl_3 , 250MHz) δ 5.15 (s, 1H, H-5), 4.14 (d, 1H, $J=9.8\text{Hz}$, H-12), 3.89-3.80 (m, 2H, H-2), 2.47 (s, 1H), 1.94-1.72 (m, 6H), 1.54 (s, 3H, CH_3 -15), 1.53-1.25 (m, 9H), 0.84 (d, 3H, $J=7.3\text{Hz}$, CH_3 -13), 0.87 (d, 3H, $J=6.6\text{Hz}$, CH_3 -14).

$^{13}\text{C-NMR}$ (CDCl_3 , 63MHz) δ 135.5, 120.9, 72.0, 62.6, 42.6, 42.5, 39.7, 37.8, 37.6, 36.0, 28.1, 27.0, 26.4, 26.2, 24.1, 20.1, 10.4.

IR(neat) ν_{max} 3435(OH), 2921, 1647, 1622, 1386, 1124, 1088, 1016 cm^{-1} MS (EI) m/z 266 ($[\text{M}^+]$), 248 ($[\text{M}^+]-\text{H}_2\text{O}$), 203 ($[\text{M}^+]-\text{C}_2\text{H}_5\text{O}$).

(2) Synthesis of 12- (2'-bromoethyl) dihydroartemisinin alcohol (XV).

12-(2'-hydroxyethyl) dihydroartemisinin alcohol (XIV) (399mg, 1.503mmol) was dissolved in dry CH_2Cl_2 (20mL) and triphenylphosphine (TPP) (393mg, 1.503mmol) was added. The solution was allowed to stir at 0°C for 30minutes. The reaction mixture was warmed to room temperature. To this reaction mixture was slowly added CBr_4 (498mg, 1.503mmol). The reaction was allowed to stir at room temperature for 30minutes and was quenched with methanol (10mL). The reaction mixture was extracted with ethyl acetate (20mL x 3) and was washed with brine (20mL x 2). The extract was dried over MgSO_4 , concentrated in vacuo and purified by silica gel column (hexane/ethyl acetate = 5/2 as eluent) to afford 12- (2'-bromoethyl) dihydroartemisinin alcohol (XV) (470mg, 95%) as a colorless oil.

$^1\text{H-NMR}$ (CDCl_3 , 250MHz) δ 5.14 (s, 1H, H-5), 4.1 (d, 1H, $J=7.5\text{Hz}$, H-12), 3.57-3.52 (t, 2H, $J=7.5\text{Hz}$), 2.31 (s, 1H), 1.94-1.71 (m, 6H), 1.54 (s, 3H, CH_3 -15), 1.53-1.25 (m, 9H), 0.84 (d, 6H, $J=5.0\text{Hz}$, CH_3 -13,14).

$^{13}\text{C-NMR}$ (CDCl_3 , 63MHz) δ 135.5, 120.7, 69.8, 42.8, 42.4, 39.1, 38.9, 37.8, 36.0, 31.9, 28.0, 27.0, 26.4, 26.1, 24.1, 20.1, 10.2.

IR (neat) ν_{max} 3427 (OH), 2910, 1726, 1447, 1378, 1259, 992, 908, 734 cm^{-1}

MS (EI) m/z 328 ($[\text{M}^+]$), 310 ($[\text{M}^+]-\text{H}_2\text{O}$), 249 ($[\text{M}^+]-\text{Br}$).

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/643,117

(3) Synthesis of the title compound

12- (2'-bromoethyl) dihydroartemisinin alcohol (XV) (250mg, 0.665mmol) was added to CH₃CN/CH₂Cl₂ (1/1, 60mL) containing catalytic Rose Bengal and then was irradiated with white light (500W tungsten lamp) at -23°C for 4 hours under oxygen. After completion of the reaction, to the reaction mixture was added saturated NaHCO₃ solution (50mL).

This mixture was extracted with diethyl ether (20mL x 3) and then washed with brine (20mL x 2). The extract was dried over MgSO₄. Solvent was evaporated under reduced pressure and the residue was dissolved in CH₃CN/CH₂Cl₂ (9/1, 10mL). This solution was cooled to -40°C. Acidic catalyst trifluoroacetic acid (TFA) was added to this solution and then was allowed to stir at -40°C for 12 hours under oxygen. The reaction mixture was quenched with saturated NH₄Cl solution (10mL) and extracted with diethyl ether (20mL x 3). The extract was washed with water (30mL x 2) and brine (30mL x 2), dried over MgSO₄, concentrated in vacuo and purified by silica gel column (hexane/ethyl acetate = 5/1 as eluent) to afford 12- (2'-bromoethyl) deoxoartemisinin (V) (99mg, 40%) as a white solid.

$[\alpha]_D^{18} = +96.3$ (c 0.1, CHCl₃).

m. p. 94°C.

¹H-NMR (CDCl₃, 500MHz) δ 5.26 (s, 1H, H-5), 4.33-4.27 (m, 1H, H-12), 3.56-3.51 (m, 2H, H-2'), 2.60-2.45 (m, 2H), 2.30 (ddd, 1H, $J=4.1, 3.8, 4.1$ Hz), 2.05-1.89 (m, 4H), 1.83-1.48 (m, 4H), 1.39 (s, 3H, CH₃-15), 1.28-1.22 (m, 2H), 0.94 (d, 3H, $J=4.8$ Hz, CH₃-13), 0.87 (d, 3H, $J=7.4$ Hz, CH₃-14), 0.78 (m, 1H).

¹³C-NMR (CDCl₃, 125MHz) δ 103.4, 89.5, 81.2, 73.2, 52.4, 44.4, 37.7, 37.3, 35.8, 34.8, 33.7, 31.6, 30.3, 26.3, 25.0, 20.4, 13.1.

IR (KBr) ν_{max} 2950, 1461, 1377, 1272, 1117, 1042, 1010, 880 (O-O), 756 cm⁻¹

MS (EI) m/z 376 (M+2), 342 ([M+]-O₂).

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

Example 2: Synthesis of 12-(2'-aminoethyl) deoxoartemisinin (VI).

(1) Synthesis of 12- (2'-ethyl azide) deoxoartemisinin (XVI).

12- (2'-bromoethyl) deoxoartemisinin (V) (128mg, 0.352mmol) was dissolved in DMF (5mL) and sodium azide (45.7mg, 0.704mmol) was added. This mixture was allowed to stir at room temperature for 5 hours. To the reaction mixture was added water (30mL). The resulting mixture was extracted with ethyl acetate (50mL x 2) and then washed with brine (40mL x 2). The extract was dried over MgSO_4 , concentrated in vacuo, then purified by silica gel column (hexane/ethyl acetate = 5/2 as eluent) to afford 12- (2'-ethyl azide) deoxoartemisinin (XVI) (109mg, 92%) as a colorless oil.

$[\alpha]_D^{23} = +64.2$ (c 0.47, CHCl_3).

$^1\text{H-NMR}$ (CDCl_3 , 250MHz) δ 5.28(s, 1H, H-5), 4.31-4.27(m, 1H, H-12), 3.56-3.53(m, 1H), 3.44-3.38(m, 1H), 2.69-2.64(m, 1H), 2.31(ddd, 1H, $J=4.1, 3.8, 4.1$ Hz), 2.03-1.75(m, 5H), 1.67-1.60(m, 3H), 1.40(s, 3H, CH_3 -15), 1.33-1.27(m, 3H), 0.96(d, 3H, $J=5.6$ Hz, CH_3 -13), 0.87(d, 3H, $J=7.5$ Hz, CH_3 -14), 0.82(m, 1H).

$^{13}\text{C-NMR}$ (CDCl_3 , 63MHz) δ 103.5, 89.5, 81.3, 72.3, 52.5, 49.8, 44.5, 37.8, 36.9, 34.7, 30.4, 29.5, 26.3, 25.1, 25.1, 20.4, 13.1.

IR(neat) ν_{max} 2927, 2875, 2095 (N_3), 1733, 1454, 1377, 1277, 1098, 1011, 880 (O-O), 756 cm^{-1} .

MS(EI) m/z 337 [M^+], 305 ([M^+]- O_2).

(2) Synthesis of the title compound.

12- (2'-ethylazide) deoxoartemisinin (XVI) (137.9mg, 0.352mmol) was dissolved in dry THF (10mL), cooled to -78°C and LAH (35.1mg, 0.925mmol) was added. The solution was allowed to stir at -78°C for 1 hour, warmed to -10°C slowly and allowed to stir at that temperature for 1 hour. The reaction mixture was extracted with ethyl acetate (50mL x 2) and washed with brine (40mL x 2). The extract was dried over MgSO_4 , concentrated in vacuo, then purified by silica gel

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

column (100% methanol as eluent) to afford 12- (2'-aminoethyl) deoxoartemisinin (VI) (85.4mg, 78%) as a white solid.

$[\alpha]^{23}_D = +38.7$ (c 0.1, CHCl_3).

m. p. 103°C.

$^1\text{H-NMR}$ (CDCl_3 , 250MHz) δ 5.32 (s, 1H, H-5), 4.29-4.21 (m, 1H, H-12), 2.93-2.84 (m, 3H), 2.69-2.64 (m, 1H), 2.32 (ddd, 1H, $J=4.0, 3.7, 4.0\text{Hz}$), 2.05-1.82 (m, 3H), 1.80-1.74 (m, 2H), 1.62-1.50 (m, 2H), 1.40 (s, 3H, CH_3 -15), 1.32-1.26 (m, 4H), 0.96 (d, 3H, $J=5.7\text{Hz}$, CH_3 -13), 0.87 (d, 3H, $J=7.5\text{Hz}$, CH_3 -14), 0.83 (m, 1H).

$^{13}\text{C-NMR}$ (CDCl_3 , 63MHz) δ 103.5, 89.4, 81.5, 74.2, 52.7, 44.7, 41.0, 37.8, 36.9, 34.8, 33.2, 30.6, 26.5, 25.1, 25.0, 20.5, 13.4.

IR(KBr) ν = 3365(NH), 2924, 2874, 1663, 1570, 1455, 1377, 1114, 1054, 1011, 944, 877 (O-O), 753 cm^{-1}

HRMS(FAB) m/z 312.2175 ($[\text{M}+\text{H}]^+$, obsd), 311.2097 (calcd for $\text{C}_{17}\text{H}_{29}\text{NO}_4$).

Elemental analysis ($\text{C}_{17}\text{H}_{29}\text{NO}_4$) C, H, N.

Example 3: Synthesis of 12- (2'-ethylsulfide) deoxoartemisinin dimer (IVa_1).

12-(2'-bromoethyl) deoxoartemisinin (V) (45mg, 0.124mmol) was dissolved in pure ethanol (4mL), allowed to stir at room temperature for 10 minutes and Na_2S (4.8mg, 0.5eq) was added. The reaction mixture was allowed to stir at room temperature for 7 hours. This reaction mixture was extracted with ethyl acetate (10mL x 3) and washed with brine (10mL x 2). The extract was dried over MgSO_4 , concentrated in vacuo, then purified by silica gel column (hexane/ethyl acetate = 5/1 as eluent) to afford 12-(2'-ethylsulfide) deoxoartemisinin dimer (IVa_1) (58.7mg, 76%) as a colorless oil.

$[\alpha]^{25}_D = +58.7$ (c 0.23, CHCl_3).

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

$^1\text{H-NMR}$ (CDCl_3 , 250MHz) δ 5.29 (s, 2H, H-5), 4.24-4.19 (m, 2H, H-12), 2.91-2.84 (m, 2H), 2.71-2.70 (m, 2H), 2.55-2.49 (m, 2H), 2.33 (ddd, 2H, $J=3.1, 3.5, 4.0\text{Hz}$), 2.03-1.78 (m, 8H), 1.67-1.55 (m, 10H), 1.41 (s, 6H, CH_3 -15), 1.36-1.26 (m, 4H), 0.96 (d, 6H, $J=5.8\text{Hz}$, CH_3 -13), 0.88 (d, 6H, $J=7.4\text{Hz}$, CH_3 -14), 0.83 (m, 2H).

$^{13}\text{C-NMR}$ (63MHz, CDCl_3) δ 103.6, 89.2, 81.4, 76.8, 75.5, 52.7, 44.8, 37.7, 36.9, 34.8, 30.5, 30.1, 26.5, 25.2, 25.0, 20.6, 13.5.

IR(neat) ν = 2925, 2876, 1617, 1459, 1379, 1119, 1054, 1011, 887 (O-O), 735 cm^{-1}

HRMS(FAB) m/z 645.3541 ($[\text{M}+\text{Na}]^+$, obsd), 622.3539 (calcd for $\text{C}_{34}\text{H}_{54}\text{O}_8\text{S}$).

Elemental analysis ($\text{C}_{34}\text{H}_{54}\text{O}_8\text{S}$) C, H, S.

Example 4: Synthesis of 12- (2'-sulfonylethyl) deoxoartemisinin dimer (IVa_2).

12-(2'-ethylsulfide) deoxoartemisinin dimer (IVa_1) (28mg, 0.041mmol) was dissolved in dry CH_2Cl_2 (2mL), allowed to stir at room temperature for 10 minutes and *m*-CPBA (15.7mg, 0.091mmol) was added slowly. The reaction mixture was allowed to stir at room temperature for 3h and saturated NaHCO_3 solution (3mL) was added. The reaction mixture was extracted with ethyl acetate (10mL x 3) and washed with brine (10mL x 2).

The extract was dried over MgSO_4 , concentrated in vacuo, then purified by silica gel column (hexane/ethyl acetate = 2/1 as eluent) to afford 12- (2'-sulfonylethyl) deoxoartemisinin dimer (IVa_2) (24.6mg, 91%) as a white solid.

$[\alpha]_D^{20} = +84.2$ (c 0.44, CHCl_3).

m. p. 98°C.

$^1\text{H-NMR}$ (CDCl_3 , 250 MHz) δ 5.30 (s, 2H, H-5), 4.25-4.18 (m, 2H, H-12), 3.53-3.41 (m, 2H, H-2), 3.05-2.935 (m, 2H, H-2), 2.79-2.71 (m, 2H), 2.36 (ddd, 2H, $J=3.2, 3.5, 4.1\text{Hz}$), 2.17-1.92 (m, 6H), 1.88-1.78 (m, 4H), 1.69-1.49 (m, 8H), 1.39 (s, 6H, CH_3 -15), 0.97 (d, 6H, $J=5.7\text{Hz}$, CH_3 -13), 0.92 (d, 6H, $J=7.6\text{Hz}$, CH_3 -14), 0.89 (m, 2H).

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

^{13}C NMR (CDCl_3 , 63MHz) δ 134. 1,130. 6,130. 1,128. 6,103. 6,89. 4,81. 4,74. 1,52. 5,44. 4. 36. 8. 30.5. 26.4. 25.2. 22.4. 20.4. 13.2.

IR(KBr) ν = 2928,2876, 1723,1575, 1449, 1380, 1280, 1123, 1052, 880 (O-O), 734 cm^{-1}

HRMS(FAB) m/z 677.3335 ($[\text{M}+\text{Na}]^+$, obsd), 654.3438 (calcd for $\text{C}_{34}\text{H}_{64}\text{O}_{10}\text{S}$).

Elemental analysis ($\text{C}_{34}\text{H}_{64}\text{O}_{10}\text{S}$) C, H, S.

Example 5: Synthesis of S, S'- [12- (2'-ethyl) deoxoartemisinin] dithiopropene dimer (IVb₁)

Powdered KOH (12.36mg, 0. 22mmol) was added to DMSO (2mL), allowed to stir at room temperature for 1 hour and then 1, 3-propanedithiol (6. 64 μL , 0. 054mmol) and 12- (2'-bromoethyl) deoxoartemisinin (V) (41mg, 0. 112mmol) was added together. The reaction mixture was allowed to stir at room temperature for 1 hour. The reaction mixture was extracted with ethyl acetate (30mL x 3) and washed with brine (20mL x 2). The extract was dried over MgSO_4 , concentrated in vacuo, then purified by silica gel column (hexane/ethyl acetate = 5/2 as eluent) to afford S, S'- [12- (2'-ethyl) deoxoartemisinin] dithiopropene dimer (IV b₁) (50.7mg, 65%) as a colorless oil.

$[\alpha]_D^{24} = +112. 3$ (c 0. 4, CHCl_3).

^1H -NMR (CDCl_3 , 250MHz) δ 5. 29 (s, 2H, H-5), 4. 22-4.17 (m, 2H, H-12), 2.83-2. 66 (m, 10H), 2.41-2. 29 (m, 2H), 2.05-1. 76 (m, 10H), 1.66-1. 53 (m, 10H), 1.41 (s, 6H, CH_3 -15), 1.33-1. 26 (m, 4H), 0.96 (d, 6H, $J=5.7\text{Hz}$, CH_3 -13) 0.88 (d, 3H, $J=7. 5\text{Hz}$, CH_3 -14), 0.83 (m, 2H).

^{13}C -NMR (CDCl_3 , 63MHz) δ 103.6, 89.3, 81.4, 75.3, 52.7, 44.7, 38.8, 37.8, 36.9, 34.8, 32.3, 30.5, 30.2, 29.11, 26.5, 25.2, 25.0, 20.5, 13.4.

IR(neat) ν = 2928, 2873, 1655,1719, 1452,1378, 1215,1120, 1036,877 (O-O), 755 cm^{-1}

HRMS(FAB) m/z 719.3701 ($[\text{M}+\text{Na}]^+$, obsd) 696.3730 (calcd for $\text{C}_{37}\text{H}_{60}\text{O}_8\text{S}_2$).

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

Elemental analysis ($C_{37}H_{60}O_8S_2$) C, H, S.

Example 6: Synthesis of S, S'- [12- (2'-ethyl) deoxoartemisinin] disulfonylpropane dimer (IVb₂).

S, S'- [12- (2'-ethyl) deoxoartemisinin] disulfonylpropane dimer (IV b₂) (22. 6mg, 72%) as a white solid was prepared by following the procedure of Example 4, but replacing 12- (2'-ethylsulfide) deoxoartemisinin dimer (IVa₁) with S, S'- [12- (2'-ethyl) deoxoartemisinin] dithiopropane dimer (IV b₁) (29mg, 0.041 mmol) and using 31. 1 mg of m-CPBA (0. 18mmol).

$[\alpha]_D^{25} = +110. 4$ (c 0.47, $CHCl_3$).

m. p. 138°C.

¹H-NMR ($CDCl_3$, 250MHz) δ 5. 30 (s, 2H, H-5), 4.25-4. 21 (m, 2H, H-12), 3.49-3. 43 (m, 2H), 3.26 (t, 2H, J=7. 1Hz), 3.04-2. 92 (m, 2H), 2.74-2. 62 (m, 2H), 2.49-2. 43 (m, 2H), 2.41-2. 29 (m, 2H), 2.08-1. 94 (m, 8H), 1.89-1. 75 (m, 4H), 1.69-1. 59 (m, 8H), 1.39 (s, 6H, CH_3 -15), 1.34-1. 27 (m, 4H), 0.97 (d, 6H, J=5. 7Hz, CH_3 -13), 0.91 (d, 6H, J=7.6Hz, CH_3 -14), 0. 88 (m, 2H).

¹³C-NMR ($CDCl_3$, 63MHz) δ 134.2, 130.6, 130.1, 128.4, 103.6, 89.5, 81.4, 74.1, 52.5, 44.3, 37.7, 36.8, 34.7, 31.3, 30.5, 26.4, 25.2, 20.4, 13.5.

IR(KBr) ν = 2926, 2875, 1720, 1584, 1495, 1387, 1310, 1130, 1052, 877 (O-O), 756, 465 cm^{-1}

HRMS (FAB) m/z 783. 3538 ($[M+Na]^+$, obsd), 760.3526 (calcd for $C_{37}H_{60}O_{12}S_2$).

Elemental analysis ($C_{37}H_{60}O_{12}S_2$) C, H, S.

Example 7: Synthesis of 12-(2'-amidethyl) deoxoartemisinin dimer (IVc).

12-carboxylethyldeoxoartemisinin (VII) (32mg, 0.086mmol), prepared by a known procedure (see Jung, M.; Freitas, A. C. C.; McChesney, J. D.; ElSohly, H. N. , A Practical and General Synthesis of (+)-Carboxyalkyldeoxoartemisinins, *Heterocycles*. 1994, 39, 23-29), was dissolved in dry CH_2Cl_2 (3mL) and HOBT

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

(38mg, 0.256mmol) and EDC (47mg, 0.256mmol) was added together. The reaction mixture was allowed to stir at room temperature for 30 minutes and 12-(2'-aminoethyl) deoxoartemisinin (VI) (30mg, 0.096mmol) was added. The resulting reaction mixture was allowed to stir at room temperature for 4 hours. The reaction mixture was extracted with ethyl acetate (20mL x 3) and washed with brine (10mL x 2). The extract was dried over MgSO_4 , concentrated in vacuo, then purified by silica gel column (hexane/ethyl acetate = 1/2 as eluent) to afford 12-(2'-aminoethyl) deoxoartemisinin dimer (IVc) in 81 % yield as a colorless oil.

$[\alpha]_D^{23} = +111.3$ (c 0.38, CHCl_3).

$^1\text{H-NMR}$ (CDCl_3 , 500MHz) δ 6.28 (s, 1H, NH), 5.30 (s, 1H, H-5), 5.29 (s, 1H, H-5), 4.33-4.31 (m, 1H, H-12), 4.06-4.04 (m, 1H, H-12), 3.58-3.56 (m, 1H, H-2), 3.28-3.26 (m, 1H, H-2), 2.73-2.69 (m, 1H), 2.65-2.62 (m, 1H), 2.51-2.44 (m, 1H), 2.35-2.32 (t, 2H, $J=13.5\text{Hz}$), 2.24-2.15 (m, 1H), 2.04-1.98 (m, 2H), 1.95-1.89 (m, 3H), 1.78-1.71 (m, 4H), 1.66-1.64 (m, 4H), 1.40 (s, 6H, CH_3 -15), 1.37-1.24 (m, 9H), 0.96 (d, 3H, $J=5.3\text{Hz}$, CH_3 -13), 0.95 (d, 3H, $J=5.7\text{Hz}$, CH_3 -13), 0.88 (d, 3H, $J=7.5\text{Hz}$, CH_3 -14), 0.86 (d, 3H, $J=7.5\text{Hz}$, CH_3 -14), 0.84 (m, 2H).

$^{13}\text{C-NMR}$ (CDCl_3 , 63MHz,) δ 173.8, 126.8, 126.1, 118.0, 111.2, 103.7, 103.5, 89.6, 89.0, 81.5, 81.4, 76.4, 74.7, 52.8, 52.5, 44.8, 44.3, 37.8, 37.6, 36.8, 35.1, 34.8, 34.7, 30.7, 30.5, 26.5, 26.4, 25.4, 25.1, 25.0, 20.5, 20.4, 13.7, 13.6.

IR(neat) ν = 3380 (NH), 2941, 2877, 1653 (C=O), 1545, 1446 (C-N), 1379, 1097, 1051, 1013, 915, 878 (O-O), 733 cm^{-1}

HRMS(FAB) m/z 634.3995 ($[\text{M}+\text{H}]^+$, obsd), 633.3877 (calcd for $\text{C}_{35}\text{H}_{55}\text{NO}_9$).

Elemental analysis ($\text{C}_{35}\text{H}_{55}\text{NO}_9$) C, H, N.

Example 8: Synthesis of 12-[2'-(N-glutamic)- α , β -amide] deoxoartemisinin dimer (IVd).

(1) Synthesis of 12-[2'-(N-tBOC-glutamic- γ -benzylester)- α -amide] deoxoartemisinin (VIII).

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

N-tBOC-L-glutamic acid- γ -benzylester (35mg, 0.11mmol) was dissolved in dry CH_2Cl_2 (5mL) and HOBt (52mg, 0.342mmol) and EDC (63mg, 0.342mmol) was added. The reaction mixture was allowed to stir at room temperature for 30 minutes and 12- (2'-aminoethyl) deoxoartemisinin (VI) (42mg, 0.135mmol) was added. The resulting reaction mixture was allowed to stir at room temperature for 3 hours. The reaction mixture was extracted with ethyl acetate (20mL x 3) and washed with brine (10mL x 2).

The extract was dried over MgSO_4 , concentrated in vacuo, then purified by silica gel column (hexane/ethyl acetate = 1/2 as eluent) to afford 12-[2'-(N-tBOC-glutamic- γ -benzylester)- α -amide] deoxoartemisinin (VII) (71.5mg, 84%) as a colorless oil.

$[\alpha]_D^{25} = +73.6$ (c 0.47, CHCl_3).

$^1\text{H-NMR}$ (CDCl_3 , 250MHz) 6.7.36 (s, 5H, aromatic H), 7.02 (br, 1H, NH), 5.33 (s, 1H, H-5), 5.11 (s, 2H, benzyl), 4.40-4.39 (m, 1H, H-12), 4.29-4.27 (m, 1H), 4.15-4.13 (m, 1H), 3.58-3.56 (m, 1H, H-2), 3.28-3.24 (m, 1H, H-2), 2.61-2.43 (m, 3H), 2.36-2.14 (m, 3H), 2.12-1.98 (m, 4H), 1.91-1.65 (m, 4H), 1.44 (s, 9H, t-BOC), 1.42 (s, 3H, CH_3 -15), 1.35-1.26 (m, 3H), 0.96 (d, 3H, $J=5.6\text{Hz}$, CH_3 -13), 0.85 (d, 3H, $J=7.6\text{Hz}$, CH_3 -14), 0.82 (m, 1H).

$^{13}\text{C-NE}$ (CDCl_3 , 63MHz) δ 173.2, 171.5, 155.2, 136.1, 128.8, 128.8, 128.5, 128.5, 128.4, 128.4, 103.8, 89.9, 81.3, 74.4, 66.6, 61.2, 53.1, 52.3, 44.0, 39.4, 37.7, 36.7, 34.6, 30.8, 28.6, 28.5, 28.5, 26.2, 25.1, 25.0, 20.4, 12.6.

IR(neat) ν = 3364 (NH), 2932, 2876, 1736 (C=O), 1663 (C=O), 1538, 1453, 1393, 1249, 1163, 1051, 880 (O-O), 702, 610 cm^{-1}

HRMS (FAB) m/z 631.3507 ($[\text{M}+\text{H}]^+$, obsd), 630.3516 (calcd for $\text{C}_{34}\text{H}_{50}\text{N}_2\text{O}_9$).

(2) Synthesis of 12-[2'-(N-tBOC-glutamic acid)- α -amide] deoxoartemisinin (IX).

12-[2'-(N-tBOC-glutamic- γ -benzylester)- α -amide] deoxoartemisinin (VIII) (36mg, 0.057mmol) was dissolved in dry THF/ H_2O (1/1, 5mL) and 1N LiOH (1mL) was added. The solution was allowed to stir at room temperature for 2 hours. The reaction solution was acidified with 1N HCl, extracted with ethyl acetate (20mL x 3), and then washed with brine (10mL x 2). The extract was

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

dried over MgSO_4 , concentrated in vacuo, then purified by silica gel column (hexane/ethyl acetate = 1/2 as eluent) to afford 12- [2'- (N-tBOC-glutamic acid)- α -amide] deoxoartemisinin (IX) (26.8mg, 87%) as a colorless oil.

$[\alpha]_D^{25} = +66.4$ (c 0.34, CHCl_3).

^1H -NMR (CDCl_3 , 250MHz) δ 5.60 (d, 1H, $J=7.9\text{Hz}$, NH), 5.33 (s, 1H, H-5), 4.34-4.32 (m, 1H, H-12), 4.20-4.15 (m, 1H), 3.49-3.47 (m, 1H, H-2), 3.33-3.31 (m, 1H, H-2), 2.66-2.58 (m, 1H), 2.48-2.40 (m, 2H), 2.30 (ddd, 1H, $J=2.2, 1.9, 3.7\text{Hz}$), 2.03-1.73 (m, 5H), 1.67-1.61 (m, 6H), 1.41 (s, 9H, t-BOC), 1.38 (s, 3H, CH_3 -15), 1.33-1.21 (m, 3H), 0.95 (d, 3H, $J=5.1\text{Hz}$, CH_3 -13), 0.84 (d, 3H, $J=7.4\text{Hz}$, CH_3 -14), 0.81 (m, 1H).

^{13}C -NMR (CDCl_3 , 63MHz) δ 176.6, 172.2, 103.7, 89.7, 81.4, 76.9, 74.7, 53.4, 52.5, 44.3, 39.1, 37.8, 36.8, 34.7, 30.7, 30.6, 29.8, 28.7, 28.7, 28.7, 28.7, 26.2, 25.2, 25.0, 20.5, 13.0.

IR(neat) ν_{max} 3352 (CO_2H and NH), 2933, 2879, 1714 ($\text{C}=\text{O}$), 1657 ($\text{C}=\text{O}$), 1533, 1459, 1379, 1275, 1170, 1053, 914, 882 (O-O), 733 cm^{-1} .

LCMS (ESI) m/z 540 ($[\text{M}+]$).

(3) Synthesis of 12- [2'- (N-tBOC-glutamic)- α, β -amide] deoxoartemisinin dimer (X).

12-[2'- (N-tBOC-glutamic acid)- α -amide]deoxoartemisinin (IX) (21mg, 0.039mmol) was dissolved in dry CH_2Cl_2 (2mL) and HOBt (22mg, 0.119mmol) and EDC (29mg, 0.119mmol) were added together. The reaction mixture was allowed to stir at room temperature for 30 minutes and 12- (2'-aminoethyl) deoxoartemisinin (VI) (18mg, 0.058mmol) was added. The resulting reaction mixture was allowed to stir at room temperature for 3 hours. The reaction mixture was extracted with ethyl acetate (20mL x 3) and washed with brine (10mL x 2). The extract was dried over MgSO_4 , concentrated in vacuo, then purified by silica gel column (hexane/ethyl acetate = 1/2 as eluent) to afford 12- [2'- (N-tBOC-glutamic)- α, β -amide] deoxoartemisinin dimer (X) (16.6mg, 51 %) as a colorless oil.

$[\alpha]_D^{25} = 114.6$ (c 0.46, CHCl_3).

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

$^1\text{H-NMR}$ (CDCl_3 , 250MHz), δ 6.71 (s, 1H, NH), 5.87 (s, 1H, NH), 5.34 (s, 1H, H-5), 5.33 (s, 1H, H-5), 4.34-4.31 (m, 2H, H-12), 4.13-4.10 (m, 1H), 3.53-3.48 (m, 2H), 3.25-3.23 (m, 2H), 2.62-2.60 (m, 2H), 2.39-2.29 (m, 6H), 2.05-1.88 (m, 8H), 1.86-1.62 (m, 12H), 1.43 (s, 9H, t-BOC), 1.39 (s, 6H, CH_3 -15), 1.28-1.25 (m, 5H), 0.96 (d, 6H, $J=5.3\text{Hz}$, CH_3 -13), 0.86 (d, 6H, $J=7.5\text{Hz}$, CH_3 -14), 0.83 (m, 2H).

$^{13}\text{C-NMR}$ (CDCl_3 , 63MHz,) δ 173.3, 173.2, 171.5, 171.4, 103.5, 103.4, 89.8, 89.6, 81.4, 81.4, 76.9, 74.3, 52.5, 52.5, 44.4, 44.3, 39.3, 37.8, 36.8, 34.7, 30.8, 28.9, 28.7, 26.4, 25.2, 25.1, 20.5, 14.5, 13.0, 12.8.

IR(neat) ν = 3379 (NH), 2877, 1713 (C=O), 1656 (C=O), 1545, 1451, 1379, 1268, 1030, 917, 880 (O-O), 732 cm^{-1}

LCMS (ESI) m/z 834 ($[\text{M}+\text{H}]$).

(4) Synthesis of the title compound.

12-[2'-(N-tBOC-glutamic)- α,β -amide] deoxoartemisinin dimer (X) (28mg, 0.036mmol) was dissolved in dry CH_2Cl_2 (2mL). To this solution was slowly added TFA (4.92mg, 1.2eq) at 0°C for 30 minutes. The resulting reaction mixture was allowed to stir at 0°C for 4 hours, extracted with ethyl acetate (20mL x 3) and washed with brine (10mL x 2).

The extract was dried over MgSO_4 , concentrated in vacuo, then purified by silica gel column (hexane/ethyl acetate = 1/2 as eluent) to afford 12-[2'-(N-glutamic)- α,β -amide] deoxoartemisinin dimer (IVd) (19mg, 72%) as a colorless oil. The dimer (IVd) is five times more water soluble (5.21 mg/ml) than artemisinin.

$[\alpha]_D^{25} = +120.8$ (c 0.48, CHCl_3).

$^1\text{H-NMR}$ (CDCl_3 , 250MHz) δ 6.83 (s, 1H, NH), 5.74 (s, 1H, NH), 5.34 (s, 1H, H-5), 5.31 (s, 1H, H-5), 4.35-4.33 (m, 2H, H-12), 4.15-4.12 (m, 1H), 3.53-3.49 (m, 2H), 3.27-3.24 (m, 2H), 2.64-2.62 (m, 2H), 2.32-2.30 (m, 2H), 2.15-1.58 (m, 12H), 1.53-1.41 (m, 10H), 1.39 (s, 6H, CH_3 -15), 1.34-1.28 (m, 6H), 0.97 (d, 6H, $J=5.3\text{Hz}$, CH_3 -14), 0.86 (d, 6H, $J=7.5\text{Hz}$, CH_3 -14), 0.82 (m, 2H).

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

^{13}C -NMR (63MHz, CDCl_3) 5173. 4,173. 3,171. 5,171. 3,103. 6,103. 4, 89. 8, 89. 7,84. 4, 84. 3,76. 9,74. 3,52. 6,52. 4,44. 5,44. 3,39. 3,37. 9,36. 7,34. 6,30. 9,30. 8, 28. 7,26. 4,25. 2, 25.1, 20.5, 20.4, 14.5, 13.3, 12.7.

IR (neat) ν = 3367 (NH), 3098 (NH), 2956, 2868, 1689 (C=O), 1558, 1446, 1380, 1209, 1137, 998, 887 (O-O), 847, 757, 729 cm^{-1}

HRMS (FAB) m/z 734.4592 ($[\text{M}+\text{H}]^+$, obsd), 733.4513 (calc for $\text{C}_{39}\text{H}_{63}\text{N}_3\text{O}_{10}$).

Elemental analysis ($\text{C}_{39}\text{H}_{63}\text{N}_3\text{O}_{10}$) C, H, N.

Example 9: Synthesis of deoxoartemisinin trimer (IVe).

(1) Synthesis of N- [12- (B-deoxoartemisinin) propionyl] -L-glutamic diethyl ester (XI). 12-carboxylethyldeoxoartemisinin (VII) (32mg, 0.256mmol) was dissolved in dry CH_2Cl_2 (3mL) and HOBT (38mg, 0.256mmol) and EDC (47mg, 0.256mmol) were added together. The reaction mixture was allowed to stir at room temperature for 30 minutes and L-glutamic diethylester (36mg, 0.171mmol) was added. The resulting reaction mixture was allowed to stir at room temperature for 3hours. The reaction mixture was extracted with ethyl acetate (20mL x 3) and washed with brine (10mL x 2). The extract was dried over MgSO_4 , concentrated in vacuo, then purified by silica gel column (hexane/ethyl acetate = 1/2 as eluent) to afford N- [12- (B-deoxoartemisinin) propionyl] -L-glutamic diethylester (XI) (37.9mg, 84%) as a colorless oil.

$[\alpha]_D^{26} = +44.5$ (c 0.47, CHCl_3).

^1H -NMR (CDCl_3 , 250MHz,) δ 6.31 (d, 1H, $J=7.5\text{Hz}$, NH), 5.29 (s, 1H, H-5), 4.63-4.56 (m, 1H), 4.23-4.08 (m, 5H), 2.75-2.71 (m, 1H), 2.50-2.18 (m, 7H), 2.04-1.65 (m, 9H), 1.40 (s, 3H, CH_3 -15), 1.31 (s, 3H), 1.28 (s, 3H), 1.22-1.15 (m, 2H), 0.96 (d, 3H, $J=5.8\text{Hz}$, CH_3 -13), 0.88 (d, 3H, $J=7.5\text{Hz}$, CH_3 -14), 0.85 (m, 1H).

^{13}C -NMR (CDCl_3 , 63MHz) δ 173. 2,172. 3,103. 7,89. 1,81. 5,76. 8,76. 3,61. 9,61. 0,52. 7, 52.0, 44.8, 37.7, 36. 8, 34.8, 34.8, 31.2, 30.7, 30.5, 27.8, 26.4, 25.2, 25.0, 20.5, 14.5, 13. 5.

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

IR(neat) ν_{max} 3370 (NH), 2939, 2878, 1737 (C=O), 1669 (C=O), 1533, 1446, 1372, 1054, 1012, 880 (O-O), 742 cm^{-1}

MS (FAB) m/z 526.5 ($[M+H]^+$).

Elemental analysis ($\text{C}_{27}\text{H}_{43}\text{NO}_9$) C, H, N.

(2) Synthesis of N-[12-(β -deoxoartemisinin)propionyl]-L-glutamic diacid (XII).

N-[12-(β -deoxoartemisinin) propionyl] -L-glutamic diethylester (XI) (2mg, 0.08mmol) was dissolved in THF/ H_2O (1/1, 5mL), 1N LiOH (1mL) was added and then was allowed to stir at room temperature for 2hours. To the reaction mixture was added 1N HCl (1mL). The resulting reaction mixture was extracted with ethyl acetate (20mL x 3) and washed with brine (10mL x 2). The extract was dried over MgSO_4 , concentrated in vacuo, then purified by silica gel column (hexane/ethyl acetate = 1/2 as eluent) to afford N-[12-(β -deoxoartemisinin) propionyl] -L-glutamic diacid (XII) (30.8mg, 82%) as a colorless oil.

$[\alpha]_D^{26} = +76.8$ (c 0.22, CHCl_3).

m. p. 106°C.

^1H -NMR (CDCl_3 , 250MHz) 8.96 (br, 2H, CO_2H), 7.08 (d, 1H, $J=6.5\text{Hz}$, NH), 5.34 (s, 1H, H-5), 4.62-4.60 (m, 1H), 4.12-4.04 (m, 1H, H-12), 2.72-2.70 (m, 1H), 2.48-2.26 (m, 6H), 2.08-1.98 (m, 3H), 1.82-1.78 (m, 3H), 1.71-1.42 (m, 4H), 1.41 (s, 3H, CH_3 -15), 1.27-1.21 (m, 2H), 0.95 (d, 3H, $J=5.3\text{Hz}$, CH_3 -13), 0.87 (d, 3H, $J=7.2\text{Hz}$, CH_3 -14), 0.84 (m, 1H).

^{13}C -NMR (CDCl_3 , 63MHz) 6177.3, 176.6, 175.1, 174.7, 104.3, 89.0, 81.5, 76.9, 52.8, 52.1, 44.9, 37.6, 36.8, 34.8, 34.5, 30.4, 27.1, 26.2, 25.1, 24.9, 21.0, 20.6, 13.7.

IR(KBr) ν_{max} 3346(CO_2H), 2942, 2877, 1728 (C=O), 1631 (C=O), 1539, 1453, 1381, 1202, 1051, 912, 880 (O-O), 732 cm^{-1}

LCMS (ESI) m/z 492 ($[M+\text{Na}]^+$).

Elemental analysis ($\text{C}_{23}\text{H}_{35}\text{NO}_9$) C, H, N.

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

(3) Synthesis of the title compound.

N-[12-(B-deoxoartemisinin)propionyl]-L-glutamic diacid (XII)(22mg, 0.047mmol) was dissolved in dry CH_2Cl_2 (2mL) and HOBt (27mg, 0.141mmol) and EDC(31mg, 0.141mmol) were added. The reaction mixture was allowed to stir at room temperature for 30 minutes and 12-(2'-aminoethyl) deoxoartemisinin (VI) (29mg, 0.093mmol) was added. The resulting reaction mixture was allowed to stir at room temperature for 19hours. The reaction mixture was extracted with ethyl acetate (30mL x 3) and washed with brine (20mL x 2). The extract was dried over MgSO_4 , concentrated in vacuo, then purified by silica gel column (hexane/ethyl acetate = 1/2 as eluent) to afford deoxoartemisinin trimer (IVe) (73.3mg, 74%) as a colorless solid.

$[\alpha]_D^{24} = +102.7$ (c 0.41, CHCl_3).

m. p. 138°C.

$^1\text{H-NMR}$ (CDCl_3 , 250MHz) δ 7.13-7.04 (m, 2H, NH), 6.83-6.81 (m, 1H, NH), 5.32 (s, 2H, H-5), 5.29 (s, 1H, H-5), 4.39-4.34 (m, 3H, H-12), 4.29-4.26 (m, 1H), 3.55-3.48 (m, 2H), 3.32-3.27 (m, 2H), 2.65-2.63 (m, 3H), 2.36-2.31 (m, 7H), 2.17-1.93 (m, 11H), 1.91-1.51 (m, 17H), 1.39 (s, 9H, CH_3 -15), 1.33-1.21 (m, 7H), 0.95 (d, 9H, $J=5.4\text{Hz}$, CH_3 -13), 0.88-0.83 (m, 9H, CH_3 -14), 0.82 (m, 3H).

$^{13}\text{C-NMR}$ (CDCl_3 , 63MHz) δ 174.4, 174.3, 173.2, 173.1, 103.5, 103.4, 89.9, 89.8, 81.5, 81.4, 76.8, 53.2, 53.1, 52.8, 52.6, 52.4, 37.7, 36.8, 34.7, 31.3, 30.8, 30.7, 30.0, 29.1, 26.4, 26.4, 25.1, 20.5, 20.4, 13.2, 13.1.

IR (KBr) ν = 3308 (NH), 2933, 2875, 1667 (C=O), 1535, 1465, 1377, 1102, 1061, 1014, 938, 874 (O-O), 751 cm^{-1}

HRMS (FAB) m/z 1056.6392 ($[\text{M}+\text{H}]^+$ obsd), 1055.6294 (calcd for $\text{C}_{57}\text{H}_{89}\text{N}_3\text{O}_{15}$).

Elemental analysis ($\text{C}_{57}\text{H}_{89}\text{N}_3\text{O}_{15}$) C, H, N.

Example 10: Synthesis of 12- (4'-aminobutyl) deoxoartemisinin (VI').

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

(1) Synthesis of 12- (4'-butyl azide) deoxoartemisinin.

12- (4'-butyl azide) deoxoartemisinin (116, 9mg, 92%) was prepared as a colorless oil by following the procedure of Example 2 (1), but replacing 12- (2'-bromoethyl) deoxoartemisinin with 12-(4'-bromobutyl)deoxoartemisinin (137.9mg, 0.352mmol).

$[\alpha]_D^{25} = +71.3$ (c 0.1, CHCl_3).

$^1\text{H-NMR}$ (CDCl_3 , 250MHz) δ 5.29 (s, 1H, H-5), 4.19-4.12 (m, 1H, H-12), 3.26 (t, 2H, $J=6.6\text{Hz}$, H-4), 2.64-2.62 (m, 1H), 2.31 (ddd, 1H, $J=4.1, 3.8, 4.1\text{Hz}$), 2.04-1.89 (m, 2H), 1.68-1.65 (m, 2H), 1.63-1.58 (m, 7H), 1.40 (s, 3H, CH_3 -15), 1.34-1.22 (m, 4H), 0.96 (d, 3H, $J=5.7\text{Hz}$, CH_3 -13), 0.86 (d, 3H, $J=7.5\text{Hz}$), 0.82 (m, 1H).

$^{13}\text{C-NMR}$ (CDCl_3 , 63MHz), δ 103.4, 89.4, 81.4, 75.3, 52.6, 51.7, 44.6, 37.7, 36.9, 34.7, 30.6, 29.3, 29.0, 26.4, 25.2, 25.0, 25.0, 20.5, 13.2.

IR (neat) ν 2927, 2876, 2095 (N_3), 1597, 1454, 1379, 1255, 1097, 1012, 946, 881 (O-O), 643 cm^{-1} .

MS (FAB) 366.4 ($[\text{M}+\text{H}]^+$).

(2) Synthesis of the title compound.

12- (4'-aminobutyl) deoxoartemisinin (VI') (94.3mg, 79%) was prepared as a white solid by following the procedure of Example 2 (2), but replacing 12- (2'-ethyl azide) deoxoartemisinin with 12- (4'-butyl azide) deoxoartemisinin (128.8mg, 0.352mmol).

$[\alpha]_D^{25} = +49.4$ (c 0.1, CHCl_3).

m. p. 105°C.

$^1\text{H-NMR}$ (CDCl_3 , 250MHz) δ 5.29 (s, 1H, H-5), 4.16-4.09 (m, 1H, H-12), 2.71-2.66 (m, 3H), 2.32 (ddd, 1H, $J=4.1, 3.8, 4.1\text{Hz}$), 2.08-2.04 (m, 2H), 1.87-1.72 (m, 3H), 1.66-1.53 (m, 4H), 1.51-1.45 (m, 4H), 1.41 (s, 3H, CH_3 -15), 1.36-1.24 (m, 4H), 0.96 (d, 3H, $J=4.3\text{Hz}$), 0.86 (d, 3H, $J=7.5\text{Hz}$), 0.83 (m, 1H).

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

^{13}C -NMR (CDCl_3 , 63MHz), δ 103.5, 89.4, 81.5, 76.0, 52.6, 51.8, 44.8, 38.4, 36.9, 34.8, 31.2, 29.4, 29.0, 26.5, 25.3, 25.2, 25.1, 20.5, 13.3.

IR (KBr) ν_{max} 3378 (NH), 2925, 1591, 1454, 1379, 1117, 1038, 1005, 887 (O-O), 748 cm^{-1}

HRMS (FAB) m/z 340.2402 ($[\text{M}+\text{H}]^+$, obsd), 339.2410 (calcd for $\text{C}_{19}\text{H}_{33}\text{NO}_4$).

Elemental analysis ($\text{C}_{19}\text{H}_{33}\text{NO}_4$) C, H, N.

Example 11: Synthesis of 12-(4'-aminobutyl)deoxoartemisinin dimer(IVc').

12-(4'-aminobutyl) deoxoartemisinin dimer (IVc') (46mg, 81%) was prepared as a colorless oil by following the procedure of Example 7, but replacing 12-(2'-aminoethyl) deoxoartemisinin with 12-(4'-aminobutyl) deoxoartemisinin (28mg, 0.096mmol).

$[\alpha]_D^{23} = +104.2$ (c 0.23, CHCl_3).

^1H -NMR (CDCl_3 , 250MHz) δ 5.68 (s, 1H, NH), 5.28 (s, 2H, H-5), 4.13-4.03 (m, 2H, H-12), 3.25-3.21 (m, 2H, H-4), 2.72-2.65 (m, 2H), 2.39-2.21 (m, 4H), 2.11-1.67 (m, 9H), 1.61-1.46 (m, 10H), 1.40 (s, 6H, CH_3 -15), 1.36-1.22 (m, 7H), 0.96 (d, 6H, $J=4.6\text{Hz}$, CH_3 -13), 0.89 (d, 3H, $J=7.4\text{Hz}$, CH_3 -14), 0.86 (d, 3H, $J=7.4\text{Hz}$, CH_3 -14), 0.83 (m, 2H).

^{13}C -NMR (CDCl_3 , 63MHz) δ 173.3, 126.5, 126.3, 118.2, 112.5, 103.7, 103.6, 89.4, 89.1, 81.5, 76.9, 76.4, 75.9, 52.8, 52.5, 44.8, 44.3, 37.8, 37.0, 36.4, 36.1, 35.2, 35.1, 34.8, 34.3, 30.6, 30.6, 26.6, 26.4, 25.2, 25.1, 25.1, 25.1, 20.6, 20.5, 13.7, 13.6.

IR(neat) ν_{max} 3388 (NH), 2936, 2875, 1650 (C=O), 1539, 1452 (C-N), 1379, 1216, 1097, 1051, 1005, 873 (O-O), 753 cm^{-1}

HRMS (FAB) m/z 662.4173 ($[\text{M}+\text{H}]^+$, obsd), 661.4190 (calcd for $\text{C}_{37}\text{H}_{59}\text{NO}_9$).

Elemental analysis ($\text{C}_{37}\text{H}_{59}\text{NO}_9$) C, H, N.

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

Example 12: Measurement of anticancer activity.

The anticancer activities of the deoxoartemisinin dimer and trimer of the present invention were measured by a known micro-culture tetrazolium assay (see Carmichel, J.; DeGraff, W. G.; Gazdar, A. F.; Minna, J. D.; Mitchell, J. B., Evaluation of a Tetrazolium-based Semiautomated Colorimetric Assay : Assessment of Chemosensitivity testing, *Cancer Res.*, 1987, 47, 936-42).

The table 1 shows cytotoxicities of the compounds of the present invention on mouse and human cancer cells *in vitro*.

Table 1

In vitro cytotoxicities (IC₅₀ (μg/mL))

	P388	EL4	Bewo	HT-29	PANC-1	SKOV3	MCF7	A549
Compound (IVa)	0.40	0.23	14.20	0.24			0.017	
Compound (IVa)	5.60	0.54	1.04	0.38			0.025	
Compound (IVb)	8.40	10.00	8.50	0.38			5.6	
Compound (IVc)	10.40	6.29	7.50	0.69		12.6	0.005	
Compound (IVc)	>20	>20	>20	20.20			>20	
Compound (IVd)	15.60	16.50	>20	6.50			15.3	
Compound (IVe)	0.12	1.07	18.30	0.09	2.69	11.2	0.017	2.45
Adriamycin	0.39	0.67	6.24	0.10			0.12	
Mitomycin	1.50	3.94	0.85	0.02			0.93	1.85
Taxol	2.27	1.34	7.39	0.01	5.76	12.30	0.0001	

P388: mouse fibroblast leukemia cell

EL4: mouse thymoma cell

Bewo: human choriocarcinoma cell

HT-29: human colorectal adenocarcinoma cell

PANC-1: human pancreatic cancer cell

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

SKOV3: human ovarian carcinoma cell

MCF7: human breast carcinoma cell

A549: human lung cancer cell

As shown in Table 1, the sulfide dimer (IVa₁) of the present invention exhibited an anticancer activity on the mouse fibroblast leukemia cell (P388), said activity being comparable to that of adriamycin and being at least 4-fold higher than that of mitomycin.

Also, the trimer (IVe) of the present invention exhibited an anticancer activity on P388, said activity being at least 3-fold higher than that of adrimycin, at least 12-fold higher than that of mitomycin and at least 20-fold higher than that of taxol. The sulfide dimer (IVa₁), sulfone dimer (IVa₂) and trimer (IVe) of the present invention exhibited an anticancer activity on the mouse thymoma cell (EL4) said activity being comparable to that of adriamycin. Most compounds had little anticancer activity on human choriocarcinoma cell (Bewo) but the sulfone dimer (IVa₂) had an anticancer activity on Bewo, which was comparable to that of mitomycin and was at least 6-fold higher than that of taxol and adriamycin. The trimer (IVe) of the present invention exhibited an anticancer activity on human colorectal adenocarcinoma cell (HT-29), said activity being comparable to that of adriamycin, and also exhibited an anticancer activity on human pancreatic cancer cell, said activity being at least 2-fold higher than that of taxol. Most compounds had little anticancer activity on human ovarian carcinoma cell (SKOV3), while the amide dimer (IVc) and trimer (IVe) of the present invention had an anticancer activity similar to that of taxol. The amide dimer (IVc), sulfide dimer (IVa₁), sulfone dimer (IVa₂) and trimer (IVe) had higher anticancer activity on human breast carcinoma cell (MCF7). Especially, the amide dimer (IVc) of the present invention exhibited an anticancer activity on MCF7, said activity being at least 24-fold higher than that of adriamycin and at least 200-fold higher than that of mitomycin. Most of the compounds had less anticancer activity on human lung cancer cell (A549), while the trimer (IVe) of the present invention had an anticancer activity on A549 similar to that of mitomycin.

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

From the results, it can be seen that the trimer (IVe) of the present invention has a very excellent anticancer activity on most mouse and human cancer cells. Also, it can be seen that the anticancer activity of the dimer of the present invention depends on the length of the linker located between two deoxoartemisinins. In other words, the compounds (IVa₁), (IVa₂) and (IVc), in which a linker has one amide-or one sulfur-centered two ethylene groups, have superior anticancer activity to the compounds (IVa₁), (IVa₂) and (IVc), in which a linker is longer than the length of two ethylene groups.

[INDUSTRIAL APPLICABILITY]


The deoxoartemisinin dimer and trimer of the present invention are C-12 non-acetal-type and do not have linker containing C-O bonds, aromatic or unsaturated groups at C-12 positions, and thus are acid stable, less toxic and have higher anticancer activity.

Also, according to the preparation of the present invention, the deoxoartemisinin analog is easily prepared in high yield.



Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/643,117

[Claims]


Claims 1. A deoxoartemisinin analog of the following formula:



In this formula ((IV), Y is -S-, -SO₂-




or




Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

2. A method for preparing deoxoartemisinin trimer of the following formula, said method comprising the steps of : coupling 12-carboxylethyldeoxoartemisinin with L-glutamic diethylester; hydrolyzing two ester groups of the product from said step; and doubly coupling the product from said step with 2 moles of 12-aminoethyldeoxoartemisinin:



3. The method as claimed in claim 2, wherein said coupling reaction is carried in the presence of ethyl-3-(3-dimethylaminopropyl) carbodiimide and 10-hydroxybenzotriazole (EDC/HOBt).

4. A deoxoartemisinin analog of the following formula :




wherein R is Br or NH₂.

5. A method for preparing 12-aminoethyldeoxoartemisinin of the following formula, said method comprising the steps of: hydroborative oxidizing a terminal

Translation of Priority Document No. 10-2003-0004511 for U.S. Application No. 10/543,117

olefin of 12-vinyldihydroartemisyl alcohol; brominating the product from said step with $\text{CBr}_4/\text{PPh}_3$; photooxygenative cyclizing the product from said step; reacting the product from said step with sodium azide; and reducing an azide group of the product from said step;



6. An anticancer agent comprising said deoxyartemisinin analog as claimed in claim 1.